Mycoplasma hyopneumoniae bacterin vaccine

Details Mycoplasma hyopneumoniae bacterin vaccine Mycoplasma hyopneumoniae bacterin vaccine

2011-06-14

2011-06-14

Graser, Jennifer E (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Combination of viral and bacterial antigens

C424S184100, C424S202100, C424S203100, C424S204100, C424S206100, C424S209100, C424S211100, C424S220100, C424S221100, C424S234100, C424S264100, C424S093100, C424S094100

Reexamination Certificate

active

07959927

ABSTRACT:
The invention provides an improvedMycoplasma hyopneumoniaebacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivatedMycoplasma hyopneumoniaebacterin and an adjuvant mixture, which, in combination, provide immunity fromMycoplasma hyopneumoniaeinfection after a single administration, and elicit an immune response specific toMycoplasma hyopneumoniaebacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA. In another embodiment, the invention provides an improvedMycoplasma hyopneumoniaebacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivatedMycoplasma hyopneumoniaebacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity fromMycoplasma hyopneumoniaeinfection after a single administration, and elicit an immune response specific toMycoplasma hyopneumoniaebacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.

REFERENCES:
patent: 3790665 (1974-02-01), Glass et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 5080896 (1992-01-01), Visser et al.
patent: 5338543 (1994-08-01), Fitzgerald et al.
patent: 6632439 (2003-10-01), Liem et al.
patent: 0 283 085 (1988-09-01), None
patent: 0 315 153 (1989-05-01), None
patent: 91/18627 (1991-12-01), None
patent: 91/18627 (1991-12-01), None
patent: 92/03157 (1992-03-01), None
patent: 92/03157 (1992-03-01), None
patent: 95/30437 (1995-11-01), None
Byars et al (Vaccine. 1987.5: 223-228).
Allison, A. C., “Squalene and Squalane Emulsions as Adjuvants,” Methods 19:87-93, 1999.
Goodwin et al., “Enzootic Pneumonia of Pigs: Immunization Attempts Inoculating Mycoplasma Suipneumoniae Antigen by Various Routes and with Different Adjuvants,” British Vet. J. 129(5):456-464, Sep.-Oct. 1973.
Byars et al., “Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity,” Vaccine, 5:223-228, Sep. 1987.
Compendium of Veterinary Products, monograph on PROSYSTEM M, Ed. A. Arrioja-Dechert, M.Sc., Fifth Ed., Jan. 1999, p. 3, Pub. A. J. Bayley, Canada.
Alexander & Brewer, “Adjuvants and their modes of action,” Livestock Production Science, 1995, pp. 153-162, vol. 42.
Hunter et al., “The Adjuvant Activity of Nonionic Block Polymer Surfactants,” J. Immunology, Sep. 1981, pp. 1244-1250, vol. 127, No. 3.

Affiliated with

Also associated with

Rating

Mycoplasma hyopneumoniae bacterin vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mycoplasma hyopneumoniae bacterin vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycoplasma hyopneumoniae bacterin vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2743982